Latest papers

Beta-ray brachytherapy of retinoblastoma: feasibility of a new small-sized ruthenium-106 plaque.

[Choroidal metastases of malignancies. Review of treatment methods with special regard to application of radiotherapy].

[Bronchial carcinoid--a rare neoplasm metastasis to choroid].

Ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal haemangioma in Sturge-Weber syndrome.

Local tumor control after 106Ru brachytherapy of choroidal melanoma.

Visual acuity after Ruthenium(106) brachytherapy of choroidal melanomas.

Ru106 brachytherapy for management of choroidal melanoma: do we need to adjust total dose according to the new NIST calibration measurement?

Forecasting the prognosis of choroidal melanoma with an artificial neural network.

Clinical quality assurance for 106Ru ophthalmic applicators.

The three-dimensional scintillation dosimetry method: test for a 106Ru eye plaque applicator.

Multilobular choroidal melanoma following ruthenium 106 brachytherapy.

[Use of ruthenuim 106 in retinoblastoma treatment].

Does the imaging method have an influence on the measured tumor height in ruthenium plaque therapy of uveal melanoma?

Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.

[Radiotherapy of intraocular tumors with Ruthenium-106-containing, beta-emitting ophthalmic applicators. Experiences with treatments performed between 1986 and 1999 in Hungary].

On the actual state of industrial quality assurance procedures with regard to (106)Ru ophthalmic plaques.

The design and the dosimetry of bi-nuclide radioactive ophthalmic applicators.

Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays)

To the Editor

[Ciliary body melanomas. Survival and prognostic aspects after brachytherapy or proton therapy].